Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 04 - 11 symbols : LLY save search
Better Together: New Licensing and Collaboration Deals to Watch
Published: 2022-04-11 (Crawled : 16:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: -2.44%
H: 3.61%
C: 2.68%
collaboration license
Inflammatory Bowel Disease Market Is Anticipated to Progress at a CAGR of 8.0% in the APAC Region for the Study Period of 2018 to 2030, Estimates DelveInsight
Published: 2022-04-11 (Crawled : 16:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 3.07%
H: 0.0%
C: -0.32%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 4.5%
H: 0.0%
C: 0.0%
GLPG | $28.9 -1.1% -1.11% 140K
|
Health Technology
|
| O: -1.31%
H: 0.06%
C: -2.47%
disease market
Lilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis
Published: 2022-04-11 (Crawled : 14:20) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
disease dermatitis
Kyttaro Announces Worldwide Exclusive Licensing Agreement With Lilly for Antibody Therapeutic Program
Published: 2022-04-11 (Crawled : 13:20) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
antibody program license
Faeth Therapeutics Expands Leadership Team with Thomas Strack as Chief Medical Officer and Virginia Casadas as Head of Clinical Operations
Published: 2022-04-11 (Crawled : 13:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
therapeutics
Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy
Published: 2022-04-11 (Crawled : 12:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: 37.7%
H: 143.24%
C: 105.01%
covid-19 drug sabizabulin phase 3
Innovent Release Phase 1 Results of IBI322 (anti-PD-L1/CD47 bispecific antibody) in patients with advanced solid tumors at AACR Annual Meeting 2022
Published: 2022-04-11 (Crawled : 01:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.82%
H: 0.59%
C: -1.88%
ibi322 results antibody phase 1
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.